Printer Friendly

BIOPLASTY LICENSES SYNTHETIC WOUND CARE DRESSING

 BIOPLASTY LICENSES SYNTHETIC WOUND CARE DRESSING
 ST. PAUL, Minn., Jan. 15 /PRNewswire/ -- Bioplasty, Inc.


(NASDAQ: BIOP), a Minnesota-based manufacturer and marketer of plastic surgery and urology products announced today that it has entered into a license agreement with Enquay Pharmaceutical Associates for its DIMAC(TM) and SILDIMAC(TM) synthetic wound care products.
 DIMAC is a polymer matrix system which can store many types and classes of drugs and chemical agents and releases the embodied material in a desirable steady-state rate so that the optimal clinical response is achieved. DIMAC serves as the storage and delivery system for the drug silver sulfadiazine to be used in the treatment of burns in burn centers and outpatient emergency rooms and has been given the trade name SILDIMAC Delivery System(TM).
 United States Patent number 4,563,184 covering these products and a New Drug Application (NDA) approval for marketing of SILDIMAC has been granted by the Food and Drug Administration.
 Bioplasty expects to begin manufacturing SILDIMAC in its new facility scheduled for completion sometime in mid-1992. SILDIMAC is expected to complement Bioplasty's existing wound care product line including MEDISKIN(R) Porcine Biological and E-Z DERM(TM) biosynthetic wound dressings.
 Bioplasty, Inc. has more than 20 years of experience in the development, manufacturing and marketing of plastic surgery products worldwide. Bioplasty's stock is currently traded on NASDAQ National Market System under the symbol BIOP.
 -0- 1/15/92
 /CONTACT: Timothy P. Lawin or Donald A. Major of Bioplasty, 612-636-4112, or Dr. Bernard Korol or Dr. Paul Nathan of Enquay Pharmaceutical Associates, 407-338-7041/
 (BIOP) CO: Bioplasty, Inc., Enquay Pharmaceutical Associates ST: Minnesota IN: MTC SU: LIC


KH -- MN009 -- 0062 01/15/92 14:02 EST
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jan 15, 1992
Words:280
Previous Article:EVANS TO HEAD DORNA, USA; APPOINTS BURNETTE AS EXECUTIVE VICE PRESIDENT
Next Article:MEI DIVERSIFIED SUBSIDIARY TO LAUNCH NEW PRODUCT LINE (Product Announcement)
Topics:


Related Articles
BIOPLASTY ANNOUNCES FIRST QUARTER OPERATING RESULTS
BIOPLASTY ANNOUNCES APPOINTMENT OF LINDA ALEXANDER TO THE POSITION OF DIRECTOR OF REGULATORY AFFAIRS
BIOPLASTY ANNOUNCES RESIGNATION OF CHIEF EXECUTIVE OFFICER AND CHAIRMAN OF THE BOARD
BIOPLASTY AGREES TO PROPOSED SETTLEMENT OF SHAREHOLDERS' SUIT
BIOPLASTY SETTLES PATENT INFRINGEMENT SUIT
BIOPLASTY, INC. ANNOUNCES PROHIBITION OF SPIN OFF RECOMMENDED
BIOPLASTY SETTLES PATENT INFRINGEMENT SUIT
BIOPLASTY, INC. ANNOUNCES RESIGNATION OF PRESIDENT AND CHIEF EXECUTIVE OFFICER
BIOPLASTY, INC. ANNOUNCES SECOND QUARTER 1993 RESULTS OF OPERATIONS
PROCYTE ACQUIRES FIVE FDA-CLEARED WOUND CARE PRODUCTS

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters